These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38586668)

  • 1. Acute Non-infectious Cystitis Secondary to Immune-Related Adverse Events in a Patient Receiving Pembrolizumab for Treatment of Non-small Cell Lung Cancer: A Case Report.
    Alhusari L; Abdallah M; Nwanwene K; Shenouda M
    Cureus; 2024 Mar; 16(3):e55666. PubMed ID: 38586668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-bacterial cystitis secondary to pembrolizumab: A case report and review of the literature.
    He X; Tu R; Zeng S; He Z; Liu S; Fang Y
    Curr Probl Cancer; 2022 Aug; 46(4):100863. PubMed ID: 35687965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of immune-related cystitis with bladder hydrodistension.
    Anraku T; Hashidate H; Imai T; Kawakami Y
    IJU Case Rep; 2023 Jul; 6(4):211-215. PubMed ID: 37405028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
    Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
    Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
    Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
    J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer.
    Baroz AR; Mambetsariev I; Fricke J; Pharaon R; Tan T; Kidambi T; Sandhu KS; Koczywas M; Salgia R
    Cureus; 2021 Jul; 13(7):e16266. PubMed ID: 34377604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent Cystitis Associated With 2 Programmed Death 1 Inhibitors: A Rare Case Report and Literature Review.
    Fan Y; Zhao J; Mi Y; Zhang Z; Geng Y; Zhou L; Shen L; Zhang Z
    J Immunother; 2023 Nov-Dec 01; 46(9):341-345. PubMed ID: 37721343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitor-Associated Thrombotic Thrombocytopenic Purpura in a Patient With Metastatic Non-Small-Cell Lung Cancer.
    De Filippis S; Moore C; Ezell K; Aggarwal K; Kelkar AH
    Cureus; 2021 Jun; 13(6):e16035. PubMed ID: 34345535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: An unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma.
    Ueki Y; Matsuki M; Kubo T; Morita R; Hirohashi Y; Sato S; Horibe R; Matsuo K; Tsukahara T; Kanaseki T; Takakuwa Y; Satoh M; Itoh N; Torigoe T
    IJU Case Rep; 2020 Nov; 3(6):266-269. PubMed ID: 33163921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.
    Barron CC; Stefanova I; Cha Y; Elsolh K; Zereshkian A; Gaafour N; McWhirter E
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
    Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
    Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
    Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
    BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer.
    Noguchi S; Suminaga K; Kaki T; Kawachi H; Fukao A; Terashita S; Horikawa S; Ikeue T; Sugita T
    Lung Cancer (Auckl); 2020; 11():53-57. PubMed ID: 32765147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
    Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
    Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
    [No Abstract]   [Full Text] [Related]  

  • 18. Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report.
    Fujimiya T; Azuma K; Togashi Y; Kuwata K; Unezaki S; Takeuchi H
    J Pharm Health Care Sci; 2024 Feb; 10(1):10. PubMed ID: 38365819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature.
    Zhou Q; Qin Z; Yan P; Wang Q; Qu J; Chen Y
    Front Immunol; 2023; 14():1226993. PubMed ID: 37869004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
    Zhang W; Gu J; Bian C; Huang G
    Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.